Quick Read – Bezos sold over 1.25 million AMZN shares via pre-scheduled 10b5-1 plans, quietly redeploying capital into Altos Labs, a private longevity biotech. – Altos Labs targets cellular rejuvenation based on Nobel-winning stem cell research, treating aging as a disease…
fecting cancer, neurodegeneration, and cardiovascular decline simultaneously. – Own a durable cash compounder first, then fund speculative long-duration bets with what it produces. Most retirement accounts cannot absorb a decade of zero returns. – Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Amazon didn’t make the cut
Grab the names FREE today. Jeff Bezos disposed of more than 1.25 million Amazon shares in early May 2026 through scheduled trading plans, with Form 4 filings showing a 1,033,597 share disposal on May 1 and a 220,200 share disposal on May 4. The capital story worth your attention sits inside a private company he has been quietly funding for years: Altos Labs, the longevity biotech Bezos backed alongside Yuri Milner, originally reported by MIT Technology Review and the Financial Times in 2022.
I’ve been following Bezos’s private deployments since the Altos news first broke, and the pattern has been consistent: he trims public exposure on a 10b5-1 schedule and redeploys into asymmetric private bets through Bezos Expeditions and his family office. Amazon (NASDAQ:AMZN) closed at $244.19 on June 9, 2026, down 10% over the past month, but those sales were scheduled long before the recent slide. What Bezos Actually Bought Altos Labs is private.